Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

Pediatr Nephrol. 2018 Nov;33(11):2137-2142. doi: 10.1007/s00467-018-3999-y. Epub 2018 Jun 28.

Abstract

Background: Ferric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described.

Methods: This is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test.

Results: The median age of this cohort was 13 years old (range 4-17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39-654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5-8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit.

Conclusions: In pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.

Keywords: CKD-MBD; Dialysis; Ferric citrate; Iron deficiency; Pediatric; Phosphate.

MeSH terms

  • Adolescent
  • Anemia, Iron-Deficiency / blood
  • Anemia, Iron-Deficiency / drug therapy*
  • Anemia, Iron-Deficiency / etiology
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Female
  • Ferric Compounds / administration & dosage*
  • Humans
  • Hyperphosphatemia / blood
  • Hyperphosphatemia / drug therapy*
  • Hyperphosphatemia / etiology
  • Male
  • Off-Label Use*
  • Phosphates / blood
  • Renal Dialysis / adverse effects
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / therapy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Ferric Compounds
  • Phosphates
  • ferric citrate